iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in…
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in…
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a…
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer…
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells…
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC)…
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1…
VANCOUVER, BC / ACCESSWIRE / April 10, 2021 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else”…
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best…